157 related articles for article (PubMed ID: 35027319)
1. An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast.
Vranic S; Gatalica Z
Clin Breast Cancer; 2022 Jun; 22(4):e576-e585. PubMed ID: 35027319
[TBL] [Abstract][Full Text] [Related]
2. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
3. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.
D'Arcy C; Quinn CM
J Clin Pathol; 2019 Jan; 72(1):7-11. PubMed ID: 30425121
[TBL] [Abstract][Full Text] [Related]
4. Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer.
Koleckova M; Ehrmann J; Bouchal J; Janikova M; Brisudova A; Srovnal J; Staffova K; Svoboda M; Slaby O; Radova L; Vomackova K; Melichar B; Veverkova L; Kolar Z
Sci Rep; 2021 Mar; 11(1):5145. PubMed ID: 33664322
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.
Vranic S; Marchiò C; Castellano I; Botta C; Scalzo MS; Bender RP; Payan-Gomez C; di Cantogno LV; Gugliotta P; Tondat F; di Celle PF; Mariani S; Gatalica Z; Sapino A
Hum Pathol; 2015 Sep; 46(9):1350-9. PubMed ID: 26208846
[TBL] [Abstract][Full Text] [Related]
6. Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers.
Vranic S; Feldman R; Gatalica Z
Bosn J Basic Med Sci; 2017 Feb; 17(1):9-11. PubMed ID: 28027454
[TBL] [Abstract][Full Text] [Related]
7. Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers.
Mills AM; E Gottlieb C; M Wendroth S; M Brenin C; Atkins KA
Am J Surg Pathol; 2016 Aug; 40(8):1109-16. PubMed ID: 27259012
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of androgen receptor and forkhead-box A1 protein in apocrine breast carcinoma.
Sasahara M; Matsui A; Ichimura Y; Hirakata Y; Murata Y; Marui E
Anticancer Res; 2014 Mar; 34(3):1261-7. PubMed ID: 24596370
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.
Dalin MG; Desrichard A; Katabi N; Makarov V; Walsh LA; Lee KW; Wang Q; Armenia J; West L; Dogan S; Wang L; Ramaswami D; Ho AL; Ganly I; Solit DB; Berger MF; Schultz ND; Reis-Filho JS; Chan TA; Morris LG
Clin Cancer Res; 2016 Sep; 22(18):4623-33. PubMed ID: 27103403
[TBL] [Abstract][Full Text] [Related]
10. Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas.
Sun X; Zuo K; Yao Q; Zhou S; Shui R; Xu X; Bi R; Yu B; Cheng Y; Tu X; Lu H; Yang W
Mod Pathol; 2020 Dec; 33(12):2473-2482. PubMed ID: 32504034
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
13. TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation.
Wang J; Peng Y; Sun H; Aung PP; Resetkova E; Yam C; Sahin AA; Huo L; Ding Q
Arch Pathol Lab Med; 2024 Feb; 148(2):200-205. PubMed ID: 37074839
[TBL] [Abstract][Full Text] [Related]
14. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer.
Naderi A; Meyer M
Breast Cancer Res; 2012 Jul; 14(4):R111. PubMed ID: 22817771
[TBL] [Abstract][Full Text] [Related]
15. Apocrine carcinoma of the breast: a comprehensive review.
Vranic S; Schmitt F; Sapino A; Costa JL; Reddy S; Castro M; Gatalica Z
Histol Histopathol; 2013 Nov; 28(11):1393-409. PubMed ID: 23771415
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm.
Jongen L; Paridaens R; Floris G; Wildiers H; Neven P
Breast Cancer Res Treat; 2016 Feb; 155(3):603-7. PubMed ID: 26868122
[TBL] [Abstract][Full Text] [Related]
17. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
[TBL] [Abstract][Full Text] [Related]
18. Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions.
Shim HS; Jung WH; Kim H; Park K; Cho NH
APMIS; 2006 May; 114(5):352-8. PubMed ID: 16725011
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous and mammary apocrine carcinomas have different immunoprofiles.
Piris A; Peng Y; Boussahmain C; Essary LR; Gudewicz TM; Hoang MP
Hum Pathol; 2014 Feb; 45(2):320-6. PubMed ID: 24342430
[TBL] [Abstract][Full Text] [Related]
20. The role of histopathologic testing on apocrine carcinoma of the breast.
Ilhan B; Emiroğlu S; Türkay R; Ilhan R
Curr Probl Cancer; 2020 Apr; 44(2):100501. PubMed ID: 31521370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]